Itay Raphael
Overview
Explore the profile of Itay Raphael including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong Z, Walsh K, Sneiderman C, Nisnboym M, Hadjipanayis C, Agnihotri S, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39949048
Background: Individual-level characteristics underlying population-level variation in glioma risk and outcomes remain incompletely understood. Cancer immunosurveillance, host immunity, and some immunotherapies center on the ability of an individual's immune cells...
2.
Rosenblum L, Sever R, Gilbert R, Guerrero D, Vincze S, Menendez D, et al.
J Transl Med
. 2024 Oct;
22(1):940.
PMID: 39407274
Background: Surgical resection is integral for the treatment of neuroblastoma, the most common extracranial solid malignancy in children. Safely locating and resecting primary tumor and remote deposits of disease remains...
3.
Nisnboym M, Sneiderman C, Jaswal A, Xiong Z, Vincze S, Sever R, et al.
Expert Rev Clin Immunol
. 2024 Oct;
21(2):239-247.
PMID: 39402706
Background: Glioblastoma (GBM) is an aggressive cancer with limited treatment options. Immunotherapy targeting CD69, an early activation marker on T cells, has shown promise in preclinical models of non-CNS malignancies....
4.
Raphael I, Mujeeb A, Ampudia-Mesias E, Sever R, McClellan B, Frederico S, et al.
bioRxiv
. 2024 Sep;
PMID: 39314283
Statement Of Significance: We demonstrate mechanisms of the druggable glioma-derived CD200 checkpoint on tumor growth and immune suppression.
5.
Frederico S, Raphael I, Nisnboym M, Huq S, Schlegel B, Sneiderman C, et al.
Expert Rev Clin Immunol
. 2024 Aug;
20(11):1411-1420.
PMID: 39114885
Objectives: Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for...
6.
Jha R, Rajasundaram D, Sneiderman C, Schlegel B, OBrien C, Xiong Z, et al.
Neuron
. 2024 Jul;
112(18):3069-3088.e4.
PMID: 39019041
Traumatic brain injury (TBI) heterogeneity remains a critical barrier to translating therapies. Identifying final common pathways/molecular signatures that integrate this heterogeneity informs biomarker and therapeutic-target development. We present the first...
7.
Pollack I, Felker J, Frederico S, Raphael I, Kohanbash G
Childs Nerv Syst
. 2024 Jun;
40(10):3263-3275.
PMID: 38884777
Pediatric low-grade gliomas (pLGGs) are the most common brain tumor types affecting children. Although gross-total resection remains the treatment of choice, many tumors are not amenable to complete removal, because...
8.
Frederico S, Sharma N, Darling C, Taori S, Dubinsky A, Zhang X, et al.
Front Pediatr
. 2024 Mar;
12:1346493.
PMID: 38523840
Pediatric high-grade glioma (pHGG) including pediatric glioblastoma (pGBM) are highly aggressive pediatric central nervous system (CNS) malignancies. pGBM comprises approximately 3% of all pediatric CNS malignancies and has a 5-year...
9.
Vincze S, Jaswal A, Frederico S, Nisnboym M, Li B, Xiong Z, et al.
Sci Rep
. 2024 Mar;
14(1):5305.
PMID: 38438420
Glioblastoma (GBM) is the most common primary malignant brain tumor. Currently, there are few effective treatment options for GBM beyond surgery and chemo-radiation, and even with these interventions, median patient...
10.
Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G
EBioMedicine
. 2024 Jan;
100:104963.
PMID: 38183840
Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard of care (SOC), various immunotherapies improve the therapeutic effect in other...